Archives2023202220212020201920182017201620152014201320122011 December 22, 2016Update on Lupuzor™ Pivotal Phase III Study – Patient Recruitment Completed Read More November 16, 2016Update on Cancer Compound IPP-204106 ‘Nucant’ Read More November 09, 2016Notification of Major Interest by Legal & General Read More October 26, 2016TR1 Notification of Major Interest Read More October 21, 2016Proposed Accelerated Bookbuild for Vendor Placing and Issue of Equity Read More October 21, 2016Close of Accelerated Bookbuild Read More September 30, 2016INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2016 Read More September 14, 2016Update on Lupuzor’s Pivotal Phase III Study – 11 US Sites Now Open, 5 European Countries Now Recruiting Read More September 07, 2016ImmuPharma Invited to Open an Additional Site in Mauritius Read More September 07, 2016ImmuPharma Invited to Open an Additional Site in Mauritius Read More June 20, 2016Northland Capital Appointed as Joint Broker Read More June 08, 2016Immupharma Hosts Lupuzor ™ Symposium with Lupuzor’s™ Inventor, Prof. Sylviane Muller Read More 123
December 22, 2016Update on Lupuzor™ Pivotal Phase III Study – Patient Recruitment Completed Read More
September 14, 2016Update on Lupuzor’s Pivotal Phase III Study – 11 US Sites Now Open, 5 European Countries Now Recruiting Read More
June 08, 2016Immupharma Hosts Lupuzor ™ Symposium with Lupuzor’s™ Inventor, Prof. Sylviane Muller Read More
